Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis
Background. COVID-19 (COrona VIrus Disease 2019) is a serious threat to cancer patients, who are at an increased risk of severe infection complications. Pre-exposure prophylaxis with a combination of monoclonal antibodies, tixagevimab-cilgavimab (Evusheld), has been shown to be effective in preventi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2023-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/611065/pdf |
| _version_ | 1797387615622660096 |
|---|---|
| author | Marina A. Lyadova Denis S. Fedorinov Evgeniya S. Kuzmina Tatiana G. Antonova Valentina K. Sokolskaya |
| author_facet | Marina A. Lyadova Denis S. Fedorinov Evgeniya S. Kuzmina Tatiana G. Antonova Valentina K. Sokolskaya |
| author_sort | Marina A. Lyadova |
| collection | DOAJ |
| description | Background. COVID-19 (COrona VIrus Disease 2019) is a serious threat to cancer patients, who are at an increased risk of severe infection complications. Pre-exposure prophylaxis with a combination of monoclonal antibodies, tixagevimab-cilgavimab (Evusheld), has been shown to be effective in preventing COVID-19, reducing hospital admission rate and mortality in immunocompromised individuals.
Aim. To describe the experience of using tixagevimab-cilgavimab for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapies.
Materials and methods. The retrospective analysis included case histories of 79 patients (57% females and 43% males) with solid tumors treated at the Moscow City Clinical Oncology Hospital No. 1 from October 2022 to June 2023. All patients received tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis.
Results. The mean age was 64±11 years (32 to 83 years). Seventy-three percent of patients received cytotoxic therapy, associated with an increased risk of infectious complications, including COVID-19. No immediate or delayed adverse events related to tixagevimab-cilgavimab were reported. During the observation period since the drug injection, 3 (3.8%) new mild cases of COVID-19 were reported.
Conclusion. Tixagevimab-cilgavimab (Evusheld) is safe and effective for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapy. |
| first_indexed | 2024-03-08T22:28:37Z |
| format | Article |
| id | doaj.art-b3cc7fa8dbb2432281fc508ed65d0c07 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-03-08T22:28:37Z |
| publishDate | 2023-12-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-b3cc7fa8dbb2432281fc508ed65d0c072023-12-18T08:35:20ZrusIP Habib O.N.Современная онкология1815-14341815-14422023-12-0125339239610.26442/18151434.2023.3.20245679512Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysisMarina A. Lyadova0https://orcid.org/0000-0002-9558-5579Denis S. Fedorinov1https://orcid.org/0000-0001-5516-7367Evgeniya S. Kuzmina2https://orcid.org/0009-0007-2856-5176Tatiana G. Antonova3https://orcid.org/0009-0007-6646-7454Valentina K. Sokolskaya4Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"Background. COVID-19 (COrona VIrus Disease 2019) is a serious threat to cancer patients, who are at an increased risk of severe infection complications. Pre-exposure prophylaxis with a combination of monoclonal antibodies, tixagevimab-cilgavimab (Evusheld), has been shown to be effective in preventing COVID-19, reducing hospital admission rate and mortality in immunocompromised individuals. Aim. To describe the experience of using tixagevimab-cilgavimab for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapies. Materials and methods. The retrospective analysis included case histories of 79 patients (57% females and 43% males) with solid tumors treated at the Moscow City Clinical Oncology Hospital No. 1 from October 2022 to June 2023. All patients received tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis. Results. The mean age was 64±11 years (32 to 83 years). Seventy-three percent of patients received cytotoxic therapy, associated with an increased risk of infectious complications, including COVID-19. No immediate or delayed adverse events related to tixagevimab-cilgavimab were reported. During the observation period since the drug injection, 3 (3.8%) new mild cases of COVID-19 were reported. Conclusion. Tixagevimab-cilgavimab (Evusheld) is safe and effective for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapy.https://modernonco.orscience.ru/1815-1434/article/viewFile/611065/pdftixagevimab-cilgavimabevusheldcovid-19chemotherapytargeted therapyimmunotherapy |
| spellingShingle | Marina A. Lyadova Denis S. Fedorinov Evgeniya S. Kuzmina Tatiana G. Antonova Valentina K. Sokolskaya Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis Современная онкология tixagevimab-cilgavimab evusheld covid-19 chemotherapy targeted therapy immunotherapy |
| title | Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis |
| title_full | Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis |
| title_fullStr | Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis |
| title_full_unstemmed | Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis |
| title_short | Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis |
| title_sort | experience with the combination of tixagevimab cilgavimab for pre exposure prophylaxis of covid 19 in cancer patients a retrospective analysis |
| topic | tixagevimab-cilgavimab evusheld covid-19 chemotherapy targeted therapy immunotherapy |
| url | https://modernonco.orscience.ru/1815-1434/article/viewFile/611065/pdf |
| work_keys_str_mv | AT marinaalyadova experiencewiththecombinationoftixagevimabcilgavimabforpreexposureprophylaxisofcovid19incancerpatientsaretrospectiveanalysis AT denissfedorinov experiencewiththecombinationoftixagevimabcilgavimabforpreexposureprophylaxisofcovid19incancerpatientsaretrospectiveanalysis AT evgeniyaskuzmina experiencewiththecombinationoftixagevimabcilgavimabforpreexposureprophylaxisofcovid19incancerpatientsaretrospectiveanalysis AT tatianagantonova experiencewiththecombinationoftixagevimabcilgavimabforpreexposureprophylaxisofcovid19incancerpatientsaretrospectiveanalysis AT valentinaksokolskaya experiencewiththecombinationoftixagevimabcilgavimabforpreexposureprophylaxisofcovid19incancerpatientsaretrospectiveanalysis |